About US
Contact us
-
Takeda decides to terminate prostate cancer drug developmentJapan-based Takeda Pharmaceutical has announced the termination of orteronel (TAK-700) development for prostate cancer in Japan, the US and Europe. The company has voluntarily decided to end the deve2014/6/24
-
Janssen enters into licence agreement with Vertex for influenza A drugJanssen Pharmaceuticals and Vertex Pharmaceuticals have entered into an exclusive licence agreement to develop, manufacture and commercialise VX-787, an investigational medicine for treatment of influ2014/6/23
-
Pfizer in cancer immunotherapy collaboration with CellectisPfizer has announced a global strategic collaboration with France-based Cellectis for development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at selec2014/6/23
-
Pfizer submits biologics license application to FDA for meningitis B vaccinePfizer has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its vaccine candidate bivalent recombinant LP2086 (rLP2086) to help protect against in2014/6/20
-
FDA to vote on opioid-induced constipation pillsTheFDAhas announced it will vote this week on whether a class of drugs that treat opioid-induced constipation needs more clinical testing in light of a side effect: heart attack. The class of drugs in2014/6/20
-
DARA BioSciences receives FDA orphan drug designation for KRN5500DARA BioSciences has received orphan drug designation from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for KRN5500, for treating multiple myeloma. Multiple myelo2014/6/19
-
Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms MarketPoor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been2014/6/19
-
With Pfizer's bid dead, AstraZeneca chief promises eyes on goalWith Pfizer's ($PFE) unwanted buyout bid in the past--at least for now--AstraZeneca ($AZN) needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted2014/6/18
-
The top 10 best-selling diabetes drugs of 2013Everybody knows that diabetes is an epidemic in this country that is costing lives and money. New stats from the U.S. Centers for Disease Control and Prevention (CDC) peg at 29.1 million the number of2014/6/18
-
Bayer’s Gadavist injection cleared for breast cancer evaluationThe US Food and Drug Administration (FDA) has approved Bayer HealthCare's Gadavist (gadobutrol) injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the US. The2014/6/17